Superiority of a Treat-to-Target Strategy over Conventional Treatment with Fixed csDMARD and Corticosteroids: A Multi-Center Randomized Controlled Trial in RA Patients with an Inadequate Response to Conventional Synthetic DMARDs, and New Therapy with Certolizumab Pegol

Background: Treatment of rheumatoid arthritis (RA) includes the use of conventional (cs), biologic (b) disease-modifying anti-rheumatic drugs (DMARDs) and oral, intramuscularly, intravenous, or intraarticular (IA) glucocorticoids (GCs). In this paper, we analysed whether a treat-to-target (T2T) stra...

Descripción completa

Detalles Bibliográficos
Autores principales: Mueller, Ruediger B., Spaeth, Michael, von Restorff, Cord, Ackermann, Christoph, Schulze-Koops, Hendrik, von Kempis, Johannes
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6462919/
https://www.ncbi.nlm.nih.gov/pubmed/30832414
http://dx.doi.org/10.3390/jcm8030302

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6462919/
https://www.ncbi.nlm.nih.gov/pubmed/30832414
http://dx.doi.org/10.3390/jcm8030302

Ejemplares similares